{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:51:28Z","timestamp":1785387088028,"version":"3.55.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Lottery Health Research"},{"DOI":"10.13039\/501100001511","name":"Auckland Medical Research Foundation","doi-asserted-by":"publisher","award":["1117015"],"award-info":[{"award-number":["1117015"]}],"id":[{"id":"10.13039\/501100001511","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.drudis.2019.01.011","type":"journal-article","created":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T03:02:08Z","timestamp":1548558128000},"page":"1627-1636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Connexin43 hemichannels: A potential drug target for the treatment of diabetic retinopathy"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4519-6727","authenticated-orcid":false,"given":"Odunayo O.","family":"Mugisho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3459-6298","authenticated-orcid":false,"given":"Colin R.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1572-8339","authenticated-orcid":false,"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5018-339X","authenticated-orcid":false,"given":"Monica L.","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5997-5994","authenticated-orcid":false,"given":"Ilva D.","family":"Rupenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2019.01.011_bib0005","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4239\/wjd.v6.i3.489","article-title":"Diabetic retinopathy \u2014 ocular complications of diabetes mellitus","volume":"6","author":"Nentwich","year":"2015","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.drudis.2019.01.011_bib0010","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2019.01.011_bib0015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","article-title":"Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury","volume":"171","author":"Nishijima","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.drudis.2019.01.011_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/a9d300ac-887d-43b3-a9b1-425d33cdf13b","article-title":"Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT study (report 4)","volume":"8","author":"Sivaprasad","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2019.01.011_bib0025","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2174\/138945013804806479","article-title":"A key role for connexin hemichannels in spreading ischemic brain injury","volume":"14","author":"Davidson","year":"2013","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.drudis.2019.01.011_bib0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/15419060802014164","article-title":"Connexin 43 mimetic peptides reduce swelling, astrogliosis, and neuronal cell death after spinal cord injury","volume":"15","author":"O\u2019","year":"2008","journal-title":"Cell Commun. Adhes."},{"key":"10.1016\/j.drudis.2019.01.011_bib0035","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/brain\/awr338","article-title":"Connexin43 mimetic peptide reduces vascular leak and retinal ganglion cell death following retinal ischaemia","volume":"135","author":"Danesh-Meyer","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.drudis.2019.01.011_bib0040","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1167\/iovs.15-16643","article-title":"Connexin43 mimetic peptide improves retinal function and reduces inflammation in a light-damaged albino rat model","volume":"57","author":"Guo","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.01.011_bib0045","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00109-018-1727-5","article-title":"Connexin43 hemichannel block protects against the development of diabetic retinopathy signs in a mouse model of the disease","volume":"97","author":"Mugisho","year":"2019","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.drudis.2019.01.011_bib0050","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbagen.2017.11.015","article-title":"The inflammasome pathway is amplified and perpetuated in an autocrine manner through connexin43 hemichannel mediated ATP release","volume":"1862","author":"Mugisho","year":"2018","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.drudis.2019.01.011_bib0055","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jdiacomp.2011.11.004","article-title":"Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy","volume":"26","author":"Ola","year":"2012","journal-title":"J. Diabetes Complications"},{"key":"10.1016\/j.drudis.2019.01.011_bib0060","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1096\/fj.03-1476fje","article-title":"A central role for inflammation in the pathogenesis of diabetic retinopathy","volume":"18","author":"Joussen","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2019.01.011_bib0065","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2217\/imt.11.24","article-title":"Anti-inflammatory therapy for diabetic retinopathy","volume":"3","author":"Zhang","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.drudis.2019.01.011_bib0070","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/bjo.82.5.561","article-title":"VEGF localisation in diabetic retinopathy","volume":"82","author":"Boulton","year":"1998","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.01.011_bib0075","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00417-010-1315-z","article-title":"A review of clinical trials of anti-VEGF agents for diabetic retinopathy","volume":"248","author":"Nicholson","year":"2010","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.01.011_bib0080","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1537-1891(03)00011-9","article-title":"Regulation of vascular permeability by vascular endothelial growth factors","volume":"39","author":"Bates","year":"2002","journal-title":"Vascul. Pharmacol."},{"key":"10.1016\/j.drudis.2019.01.011_bib0085","first-page":"819","article-title":"The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas","volume":"74","author":"Murata","year":"1996","journal-title":"Lab. Investig."},{"key":"10.1016\/j.drudis.2019.01.011_bib0090","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.visres.2017.05.005","article-title":"VEGF production and signaling in Muller glia are critical to modulating vascular function and neuronal integrity in diabetic retinopathy and hypoxic retinal vascular diseases","volume":"139","author":"Le","year":"2017","journal-title":"Vision Res."},{"key":"10.1016\/j.drudis.2019.01.011_bib0095","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1073\/pnas.92.3.905","article-title":"Vascular endothelial growth factor\/vascular permeability factor expression in a mouse model of retinal neovascularization","volume":"92","author":"Pierce","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.drudis.2019.01.011_bib0100","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/diab.46.9.1473","article-title":"Vascular endothelial growth factor?induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective \u03b2-isoform\u2013selective inhibitor","volume":"46","author":"Aiello","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.drudis.2019.01.011_bib0105","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1073\/pnas.92.23.10457","article-title":"Suppression of retinal neovascularization in-vivo by inhibition of vascular endothelial growth-factor (VEGF) using soluble VEGF-receptor chimeric proteins","volume":"92","author":"Aiello","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.drudis.2019.01.011_bib0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0140-6736(64)90008-X","article-title":"Diabetic retinopathy and rheumatoid arthritis","volume":"284","author":"Powell","year":"1964","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2019.01.011_bib0115","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.2337\/diabetes.54.5.1559","article-title":"Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy","volume":"54","author":"Krady","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.drudis.2019.01.011_bib0120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1755-8794-1-26","article-title":"Whole genome assessment of the retinal response to diabetes reveals a progressive neurovascular inflammatory response","volume":"1","author":"Brucklacher","year":"2008","journal-title":"BMC Med. Genomics"},{"key":"10.1016\/j.drudis.2019.01.011_bib0125","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/sj.eye.6702138","article-title":"Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy","volume":"20","author":"Demircan","year":"2006","journal-title":"Eye"},{"key":"10.1016\/j.drudis.2019.01.011_bib0130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.diabres.2006.04.017","article-title":"Role of monocyte chemotactic protein-1 and nuclear factor kappa B in the pathogenesis of proliferative diabetic retinopathy","volume":"74","author":"Harada","year":"2006","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.drudis.2019.01.011_bib0135","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1159\/000050900","article-title":"Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy","volume":"215","author":"Mitamura","year":"2001","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.drudis.2019.01.011_bib0140","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2004-08-3178","article-title":"Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A","volume":"105","author":"Hong","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.01.011_bib0145","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2337\/diabetes.48.5.1131","article-title":"Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells","volume":"48","author":"Marumo","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.drudis.2019.01.011_bib0150","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.drudis.2019.01.011_bib0155","first-page":"15","article-title":"Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives","volume":"8","author":"Ozaki","year":"2015","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.drudis.2019.01.011_bib0160","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nature04515","article-title":"Cryopyrin activates the inflammasome in response to toxins and ATP","volume":"440","author":"Mariathasan","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2019.01.011_bib0165","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.cell.2012.07.007","article-title":"TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria","volume":"150","author":"Rathinam","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2019.01.011_bib0170","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ni.1831","article-title":"Thioredoxin-interacting protein links oxidative stress to inflammasome activation","volume":"11","author":"Zhou","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.drudis.2019.01.011_bib0175","doi-asserted-by":"crossref","DOI":"10.1038\/ni.1935","article-title":"Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1 beta in type 2 diabetes","volume":"11","author":"Masters","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.drudis.2019.01.011_bib0180","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drudis.2019.01.011_bib0185","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2174\/1871527315666160321111829","article-title":"NLRP3 is involved in ischemia\/reperfusion injury","volume":"15","author":"Guo","year":"2016","journal-title":"CNS Neurol. Disord."},{"key":"10.1016\/j.drudis.2019.01.011_bib0190","series-title":"Retinal Degenerative Diseases","first-page":"59","article-title":"The NLRP3 inflammasome and its role in age-related macular degeneration","author":"Ildefonso","year":"2016"},{"key":"10.1016\/j.drudis.2019.01.011_bib0195","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/aos.13427","article-title":"NLRP3 inflammasome activation is associated with proliferative diabetic retinopathy","volume":"95","author":"Loukovaara","year":"2017","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.drudis.2019.01.011_bib0200","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1038\/s41598-018-21198-z","article-title":"The NLRP3 inflammasome may contribute to pathologic neovascularization in the advanced stages of diabetic retinopathy","volume":"8","author":"Chaurasia","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2019.01.011_bib0205","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1100\/tsw.2008.25","article-title":"Update on the treatment of diabetic retinopathy","volume":"8","author":"Wilkinson-Berka","year":"2008","journal-title":"Sci. World J."},{"key":"10.1016\/j.drudis.2019.01.011_bib0210","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.2337\/db05-1635","article-title":"Diabetic retinopathy: seeing beyond glucose-induced microvascular disease","volume":"55","author":"Antonetti","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.drudis.2019.01.011_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/eye.2016.208","article-title":"Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents","volume":"31","author":"Gemenetzi","year":"2017","journal-title":"Eye"},{"key":"10.1016\/j.drudis.2019.01.011_bib0220","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2019.01.011_bib0225","first-page":"485","article-title":"Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration","volume":"7","author":"Tranos","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.drudis.2019.01.011_bib0230","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.lfs.2007.08.024","article-title":"Triamcinolone acetonide protects the rat retina from STZ-induced acute inflammation and early vascular leakage","volume":"81","author":"Kim","year":"2007","journal-title":"Life Sci."},{"key":"10.1016\/j.drudis.2019.01.011_bib0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00592-012-0449-3","article-title":"Pathophysiology and treatment of diabetic retinopathy","volume":"50","author":"Bandello","year":"2013","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.drudis.2019.01.011_bib0240","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1590\/S0100-879X1999000800014","article-title":"A simple RT-PCR-based strategy for screening connexin identity","volume":"32","author":"Urban","year":"1999","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.drudis.2019.01.011_bib0245","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/cac.10.4-6.173.180","article-title":"An update on connexin genes and their nomenclature in mouse and man","volume":"10","author":"S\u00f6hl","year":"2003","journal-title":"Cell Commun. Adhes."},{"key":"10.1016\/j.drudis.2019.01.011_bib0250","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev.physiol.61.1.283","article-title":"Genetic diseases and gene knockouts reveal diverse connexin functions","volume":"61","author":"White","year":"1999","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.drudis.2019.01.011_bib0255","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.preteyeres.2015.09.004","article-title":"Connexin43 in retinal injury and disease","volume":"51","author":"Danesh-Meyer","year":"2016","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.drudis.2019.01.011_bib0260","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/cdd.2008.196","article-title":"Connexin-related signaling in cell death: to live or let die?","volume":"16","author":"Decrock","year":"2009","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.drudis.2019.01.011_bib0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/aja.1002000102","article-title":"Expression of gap junction proteins Cx26, Cx31 1, Cx37, and Cx43 in developing and mature rat epidermis","volume":"200","author":"Goliger","year":"1994","journal-title":"Dev. Dyn."},{"key":"10.1016\/j.drudis.2019.01.011_bib0270","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1242\/jcs.03320","article-title":"Acute downregulation of connexin43 at wound sites leads to a reduced inflammatory response, enhanced keratinocyte proliferation and wound fibroblast migration","volume":"119","author":"Mori","year":"2006","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.drudis.2019.01.011_bib0275","series-title":"Connexin Cell Communication Channels: Roles in the Immune System and Immunopathology","year":"2013"},{"key":"10.1016\/j.drudis.2019.01.011_bib0280","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.cub.2003.09.007","article-title":"Targeting connexin43 expression accelerates the rate of wound repair","volume":"13","author":"Qiu","year":"2003","journal-title":"Curr. Biol."},{"key":"10.1016\/j.drudis.2019.01.011_bib0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20060175","article-title":"The gap junction cellular internet: connexin hemichannels enter the signalling limelight","volume":"397","author":"Evans","year":"2006","journal-title":"Biochem. J."},{"key":"10.1016\/j.drudis.2019.01.011_bib0290","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00395-012-0309-x","article-title":"Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia\/reperfusion injury","volume":"108","author":"Wang","year":"2013","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.drudis.2019.01.011_bib0295","doi-asserted-by":"crossref","first-page":"11388","DOI":"10.1073\/pnas.1434298100","article-title":"Gating and regulation of connexin 43 hemichannels","volume":"100","author":"Contreras","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.drudis.2019.01.011_bib0300","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fphar.2013.00088","article-title":"Connexin and pannexin hemichannels in brain glial cells: properties, pharmacology, and roles","volume":"4","author":"Giaume","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drudis.2019.01.011_bib0305","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.febslet.2014.02.003","article-title":"Connexin hemichannel induced vascular leak suggests a new paradigm for cancer therapy","volume":"588","author":"Zhang","year":"2014","journal-title":"FEBS Lett."},{"key":"10.1016\/j.drudis.2019.01.011_bib0310","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1124\/pr.115.012062","article-title":"Connexins in cardiovascular and neurovascular health and disease: pharmacological implications","volume":"69","author":"Leybaert","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.drudis.2019.01.011_bib0315","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1126\/science.1967852","article-title":"Glutamate induces calcium waves in cultured astrocytes: long-range glial signaling","volume":"247","author":"Cornell-Bell","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.drudis.2019.01.011_bib0320","doi-asserted-by":"crossref","first-page":"9254","DOI":"10.1523\/JNEUROSCI.23-27-09254.2003","article-title":"Signaling at the gliovascular interface","volume":"23","author":"Simard","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2019.01.011_bib0325","doi-asserted-by":"crossref","first-page":"44606","DOI":"10.1074\/jbc.M408035200","article-title":"Platelet-activating factor-induced chemokine gene expression requires NF-\u03baB activation and Ca2+\/calcineurin signaling pathways inhibition by receptor phosphorylation and \u03b2-arrestin recruitment","volume":"279","author":"Venkatesha","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2019.01.011_bib0330","doi-asserted-by":"crossref","first-page":"E5934","DOI":"10.1073\/pnas.1803907115","article-title":"Suppression of connexin 43 phosphorylation promotes astrocyte survival and vascular regeneration in proliferative retinopathy","volume":"115","author":"Slavi","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.drudis.2019.01.011_bib0335","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1038\/jcbfm.2011.86","article-title":"Connexin channels provide a target to manipulate brain endothelial calcium dynamics and blood?brain barrier permeability","volume":"31","author":"De Bock","year":"2011","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.drudis.2019.01.011_bib0340","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1167\/iovs.10-5264","article-title":"Effects of ischemic preconditioning and bevacizumab on apoptosis and vascular permeability following retinal ischemia-reperfusion injury","volume":"51","author":"Abcouwer","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.01.011_bib0345","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.preteyeres.2008.09.003","article-title":"Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management","volume":"27","author":"Kaur","year":"2008","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.drudis.2019.01.011_bib0350","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/path.2195","article-title":"Blood-retinal barrier disruption and ultrastructural changes in the hypoxic retina in adult rats: the beneficial effect of melatonin administration","volume":"212","author":"Kaur","year":"2007","journal-title":"J. Pathol."},{"key":"10.1016\/j.drudis.2019.01.011_bib0355","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0014-4835(05)80048-X","article-title":"Blood-retinal barrier breakdown following experimental retinal ischemia and reperfusion","volume":"61","author":"Wilson","year":"1995","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.drudis.2019.01.011_bib0360","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/cne.21481","article-title":"Metabolic and functional profiling of the ischemic\/reperfused rat retina","volume":"505","author":"Sun","year":"2007","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.drudis.2019.01.011_bib0365","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s13346-015-0249-8","article-title":"Intravitreal injection of lipoamino acid-modified connexin43 mimetic peptide enhances neuroprotection after retinal ischemia","volume":"5","author":"Chen","year":"2015","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.drudis.2019.01.011_bib0370","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ejpb.2014.12.005","article-title":"Sustained intravitreal delivery of connexin43 mimetic peptide by poly(D,L-lactide-co-glycolide) acid micro-and nanoparticles\u2014Closing the gap in retinal ischaemia","volume":"95","author":"Chen","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.drudis.2019.01.011_bib0375","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biomaterials.2018.03.034","article-title":"Hyaluronic acid coated albumin nanoparticles for targeted peptide delivery in the treatment of retinal ischaemia","volume":"168","author":"Huang","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2019.01.011_bib0380","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s13311-017-0536-9","article-title":"Tonabersat prevents inflammatory damage in the central nervous system by blocking connexin43 hemichannels","volume":"14","author":"Kim","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.drudis.2019.01.011_bib0385","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1167\/iovs.13-11763","article-title":"Effects of high glucose-induced Cx43 downregulation on occludin and ZO-1 expression and tight junction barrier function in retinal endothelial cells","volume":"54","author":"Tien","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.01.011_bib0390","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2337\/diabetes.51.5.1565","article-title":"Downregulation of connexin 43 expression by high glucose reduces gap junction activity in microvascular endothelial cells","volume":"51","author":"Sato","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.drudis.2019.01.011_bib0395","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1167\/iovs.09-4489","article-title":"Reduced connexin 43 expression and its effect on the development of vascular lesions in retinas of diabetic mice","volume":"51","author":"Bobbie","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.01.011_bib0400","first-page":"732","article-title":"Downregulation of Connexin43 promotes vascular cell loss and excess permeability associated with the development of vascular lesions in the diabetic retina","volume":"20","author":"Tien","year":"2014","journal-title":"Mol. Vis."},{"key":"10.1016\/j.drudis.2019.01.011_bib0405","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.exer.2015.12.011","article-title":"Association of reduced Connexin43 expression with retinal vascular lesions in human diabetic retinopathy","volume":"146","author":"Tien","year":"2016","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.drudis.2019.01.011_bib0410","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/ceo.12084","article-title":"Absence of clinical correlates of diabetic retinopathy in the Ins2Akita retina","volume":"41","author":"McLenachan","year":"2013","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.01.011_bib0415","doi-asserted-by":"crossref","first-page":"6488","DOI":"10.1167\/iovs.12-9758","article-title":"Reduced ocular blood flow as an early indicator of diabetic retinopathy in a mouse model of diabetes","volume":"53","author":"Muir","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.01.011_bib0420","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.exer.2015.06.023","article-title":"Angiography reveals novel features of the retinal vasculature in healthy and diabetic mice","volume":"138","author":"McLenachan","year":"2015","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.drudis.2019.01.011_bib0425","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.2353\/ajpath.2010.090883","article-title":"Characterization of a mouse model of hyperglycemia and retinal neovascularization","volume":"177","author":"Rakoczy","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.drudis.2019.01.011_bib0430","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.exer.2014.03.005","article-title":"Molecular analysis of blood-retinal barrier loss in the Akimba mouse, a model of advanced diabetic retinopathy","volume":"122","author":"Wisniewska-Kruk","year":"2014","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.drudis.2019.01.011_bib0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202156","article-title":"Intravitreal pro-inflammatory cytokines in non-obese diabetic mice: modelling signs of diabetic retinopathy","volume":"13","author":"Mugisho","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2019.01.011_bib0440","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.3390\/ijms18122567","article-title":"Immunohistochemical characterization of Connexin43 expression in a mouse model of diabetic retinopathy and in human donor retinas","volume":"18","author":"Mugisho","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drudis.2019.01.011_bib0445","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1167\/iovs.17-22816","article-title":"Enhanced expression of NLRP3 inflammasome-related inflammation in diabetic retinopathy","volume":"59","author":"Chen","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618303933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618303933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:42:17Z","timestamp":1761223337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644618303933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":89,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1359644618303933"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2019.01.011","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Connexin43 hemichannels: A potential drug target for the treatment of diabetic retinopathy","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2019.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}